Citadel Advisors
FHTX icon

Citadel Advisors’s Foghorn Therapeutics FHTX Stock Holding History

Citadel Advisors’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,400
Closed -$22.3K – 14765
2024
Q3 		$22.3K Buy
2,400
+600
+33% +$4.34K ﹤0.01% 12700
2024
Q2 		$10.3K Buy
1,800
+400
+29% +$2.38K ﹤0.01% 13091
2024
Q1 		$9.39K Buy
+1,400
New +$7.77K ﹤0.01% 13504
2023
Q2 		– Sell
-2,800
Closed -$17.4K – 14601
2023
Q1 		$17.4K Buy
2,800
+500
+22% +$3.27K ﹤0.01% 13160
2022
Q4 		$14.7K Buy
+2,300
New +$17.3K ﹤0.01% 13381
2022
Q1 		– Sell
-12,000
Closed -$274K – 13896
2021
Q4 		$274K Buy
+12,000
New +$172K ﹤0.01% 11108

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Citadel Advisors's FHTX Position: Q1 2026 in Review

Citadel Advisors increased its Foghorn Therapeutics (FHTX) stake by 9.7% in Q1 2026, buying an estimated $97.4K and bringing the position to 200,013 shares worth $956K. The position accounts for ﹤0.01% of the portfolio, ranked #7755.

Citadel Advisors first reported a position in FHTX in Q1 2022 and has held it in 10 quarters since. The position peaked at $984K in Q4 2025. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Citadel Advisors held 200,013 shares of Foghorn Therapeutics worth $956K as of Q1 2026.
  • Citadel Advisors bought 17,737 Foghorn Therapeutics shares in Q1 2026, an estimated $97.4K.
  • Foghorn Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7755 holding.
  • Citadel Advisors first reported a position in Foghorn Therapeutics in Q1 2022 and has held it in 10 quarters since.
  • Citadel Advisors's Foghorn Therapeutics position peaked at $984K in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.